Unveiling ACADL: A Breakthrough Biomarker for Mesothelioma Diagnosis in Elderly Americans

ByHolly Zink
Unveiling ACADL: A Breakthrough Biomarker for Mesothelioma Diagnosis in Elderly Americans

Mesothelioma, a rare cancer linked to asbestos, is dangerous for elderly Americans. It’s hard to tell the difference between reactive and cancerous cells. However, a recent study in the American Journal of Pathology sheds light. The study identifies a key biomarker, ACADL, using advanced analysis methods.

Understanding the Challenge

Mesothelioma is usually diagnosed after a person experiences symptoms and visits a doctor. One thing a doctor may do is perform a tissue biopsy. The doctor will remove a part of the tissue (suspected mesothelioma) for examination.

Most tissue biopsies are done with a needle and examined in a laboratory. The lab looks for specific biomarkers to determine whether the tissue contains mesothelioma. Reactive mesothelial cells closely mimic malignant mesothelioma cells, complicating doctors’ accurate diagnosis.

This challenge shows the critical need for specific biomarkers. Biomarkers help to tell apart benign and malignant cells. This is vital for patients who may face health risks from past asbestos exposure.

A new study analyzed gene expression data from various sources. It found ACADL and three other markers that might separate mesothelial from mesothelioma cells. Machine learning tools like LASSO, SVM-RFE, and random forest identified these markers. Among them, ACADL stood out.

Validation in separate datasets confirmed ACADL’s diagnostic potential. It stands out in telling apart reactive cells from cancer cells. Immunohistochemistry tests showed ACADL’s specificity. It stained mesothelial cells but showed low expression in cancer cells.

Implications for Mesothelioma Patients

Older Americans, exposed to asbestos years ago, now have hope with ACADL as a biomarker. It aids in diagnosing mesothelioma accurately. This leads to timely treatments and better strategies for individual needs.

Finding ACADL as a mesothelial cell marker is a big step in diagnosing mesothelioma. More research is needed. This includes larger clinical studies and functional experiments. The goal is to understand ACADL’s role and its potential in treating mesothelioma.

In the world of mesothelioma diagnosis, ACADL stands out as a beacon of hope for elderly Americans and individuals worldwide. ACADL can distinguish between reactive and malignant mesothelioma cells, making healthcare more accurate and personalized. As research advances, it could lead to better outcomes and a higher quality of life for those with the disease.

Source:

Yin, Yige, Qianwen Cui, Jiarong Zhao, Qiang Wu, Qiuyan Sun, Hong-qiang Wang, and Wulin Yang. “Integrated Bioinformatics and Machine Learning Analysis Identify ACADL as a Potent Biomarker of Reactive Mesothelial Cells.” The American Journal of Pathology, April 22, 2024. https://doi.org/10.1016/j.ajpath.2024.03.013.

 

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    ByAlex Strauss

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…

  • |

    Sharp Rise in Mesothelin May Signal Mesothelioma

    ByAlex Strauss

    Another study has confirmed that the biomarker mesothelin may be a valuable warning sign ofmesothelioma in asbestos-exposed workers. In fact, it may rise sharply in the months preceding the onset of symptoms. Medical researchers have long known that exposure to the mineral asbestos dramatically increases the risk of developing malignant pleural mesothelioma. But doctors have struggled to find a way to identify which asbestos-exposed people are at highest risk. It is a significant problem because, as the authors of a new German study on the subject observe, “In patients developing malignant pleural mesothelioma (MPM) or lung cancer, using effective tumour markers is the quickest way to ensure early diagnosis and improve survival time.” But which biomarkers to focus on and how…

  • |

    Biomarker Test Next Step for New Mesothelioma Drug

    ByAlex Strauss

    A company that makes stem cell-focused treatments for cancer has taken an important step closer to testing a promising new mesothelioma drug. The biopharmaceutical company Verastem, Inc. specializes in agents that destroy cancer by killing cancer stem cells. One of its lead medicines is VS-6063, a focal adhesion kinase inhibitor scheduled to be the subject of a mesothelioma study later this year. In a Phase I safety study of 36 patients conducted by Pfizer (original developers of VS-6063), the drug was “well-tolerated” and showed enough efficacy to warrant further, larger studies. A focal adhesion kinase (FAK) inhibitor is an agent that regulates the growth and spread of tumor cells by inhibited a crucial signaling pathway. In preclinical cancer models, when this…

  • |

    Mesothelioma Diagnosis: SMRP Not the Answer

    ByAlex Strauss

    Soluble mesothelin-related protein (SMRP), a protein found in the blood serum of some people, may not be as effective a biomarker for mesothelioma as it was once thought to be. Malignant mesothelioma is a cancer of the internal membranes that surround the lungs, abdominal organs or heart. It is most often triggered by exposure to asbestos and is difficult to diagnose in its early stages. Biomarkers, like SMRP, are often used to try to make cancer diagnoses earlier since these compounds are often produced in larger quantities by cancer cells than by healthy cells. But in a report in Clinical Chemistry and Laboratory Medicine, a team of researchers suggests that SMRP has some significant limitations when it comes to detecting mesothelioma. The…

  • |

    New Biomarker May Detect Mesothelioma Earlier

    ByAlex Strauss

    Researchers at one of the country’s top cancer centers say they have found an effective way to diagnose mesothelioma earlier. Their findings are published in the latest issue of the prestigious New England Journal of Medicine. Fibulin-3 is a protein that is expressed in the membranes of blood vessels. A single mutation in the gene that encodes fibulin-3 has been implicated in a form of macular degeneration. Now, study author and professor of thoracic oncology Harvey Pass, MD, and his colleagues at New York University’s Langone Medical Center believe that fibulin-3 levels in the blood and pleural effusions (fluid around the lungs) can distinguish mesothelioma patients from those who have been exposed to asbestos but do not have the disease. It…